Home / Health / New Blood Test Could End Invasive Cancer Checks
New Blood Test Could End Invasive Cancer Checks
8 Jul
Summary
- AI blood test analyzes 30 markers to predict cancer risk.
- Test costs around £30 and could spare thousands invasive procedures.
- Accurately identified 99.1% of cancers as high risk.
A groundbreaking AI-driven blood test, named PinPoint, is set to revolutionize gynaecological cancer screening by potentially eliminating the need for invasive examinations. This innovative test analyzes 30 specific markers in a patient's blood to predict their risk of developing cancer as low, elevated, or high.
The cost-effective PinPoint test, estimated at around £30, has the potential to spare tens of thousands of women each year from undergoing uncomfortable and stressful diagnostic procedures. Currently, a large number of referrals for post-menopausal bleeding do not result in a cancer diagnosis, highlighting the need for a more efficient screening method.
PinPoint's technology showed exceptional accuracy in trials, correctly identifying 99.1% of cancers as elevated or high risk, with a 99.8% negative predictive value for those in the lowest risk group. This clinical evidence suggests the test can effectively support clinicians in prioritizing patients based on biological urgency, offering a scalable and safe alternative to traditional diagnostics.
